2021
Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis
Caroppo F, Galderisi A, Ventura L, Belloni Fortina A. Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis. European Journal Of Pediatrics 2021, 180: 1739-1745. PMID: 33483797, PMCID: PMC8105196, DOI: 10.1007/s00431-020-03924-w.Peer-Reviewed Original ResearchConceptsPre-pubertal childrenMetabolic syndromeInsulin resistanceMetabolic diseasesMetabolic syndrome risk factorsSingle-center prospective studyHomeostatic model assessmentAge-specific percentilesCardiometabolic comorbiditiesChildhood psoriasisProspective studyRisk factorsHigh prevalencePsoriasisModel assessmentSyndromePrevalenceLimited dataYoung childrenChildrenAdultsDiseaseComorbiditiesHOMADiagnosis
2020
Protecting youth from the vaping epidemic
Galderisi A, Ferraro V, Caserotti M, Quareni L, Perilongo G, Baraldi E. Protecting youth from the vaping epidemic. Pediatric Allergy And Immunology 2020, 31: 66-68. PMID: 33236441, DOI: 10.1111/pai.13348.Commentaries, Editorials and LettersConceptsE-cigsProduct use-associated lung injuryE-cigarettesUse-associated lung injuryPrimary care interventionsPrimary care settingE-cig userE-cig liquidsE-cig productsAirway irritantsLung injuryAsthma prevalenceCare interventionsTobacco addictionNicotine initiationCare settingsTobacco consumptionTobacco productsPediatric usersPublic healthAdolescentsAdultsEpidemicYounger onesPotential benefits978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
FORLENZA G, BUCKINGHAM B, SHERR J, WADWA R, GALDERISI A, EKHLASPOUR L, BERGET C, HSU L, ZGORSKI M, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-978-p.Peer-Reviewed Original ResearchDiabetes careMeal bolusEli LillyPercent timeRisk of hypoglycemiaAdvisory PanelType 1 diabetesHigh-fat dinnerMannKind CorporationHybrid closed-loop systemT1D durationGlucose targetsT1D ExchangeGlucose managementPivotal studiesDaily exerciseInvestigational deviceDlTarget glucoseCareLexicon PharmaceuticalsMedtronicBolusLower targetsAdults
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdults